Nalbuphine ER clinical trials

A Randomized, Double-Blind, Placebo-Controlled, Parallel, 4-Arm Dose Ranging Study of the Safety and Efficacy of Nalbuphine Extended-Release Tablets (NAL ER) for the Treatment of Cough in Idiopathic Pulmonary Fibrosis (IPF)

This study is testing a new tablet, called NAL ER, to see if it can help reduce coughing in people with Idiopathic Pulmonary Fibrosis (IPF). Researchers want to find out if it is safe and if different doses work better than a dummy pill (placebo).